Bangalore Bioinnovation Centre (BBC) and Cytiva have collaborated to work together to support the start-up ecosystem and academia in the field of biopharmaceuticals by providing a platform for skill development and industry-oriented training in the field of bioprocessing (upstream, downstream and analytical characterisation), the companies said in a joint statement.
As per Invest India’s survey, Indian biotechnology industry, estimated to reach $150 billion by 2025, expects to see the number of startups grow from above 4,000 to 10,000 by 2025. BBC is a world-class incubation centre with central instrumentation facility in a 10-acre campus with a total build-up area of 60,000 square feet, and is engaged in providing infrastructure support, skill development and assistance to start-up companies, ventures and projects in biopharmaceutical field to help conversion of innovative ideas and research into commercialisation. This collaboration aligns well in giving impetus to the innovation ecosystem by driving industry-academia linkages, and eventually, enhanced research, added the statement.
Talent is critical for all industries, but it is particularly critical for the biopharma industry given the complexity of the sector. According to the Cytiva Biopharma Resilience Index, the talent pool is the weakest link in the global biopharma industry. Sixty five per cent of the Indian respondents in the Biopharma Resilience Index say that sourcing talent in technology, manufacturing and R&D is a substantial challenge. Thus, the demand for collaboration is expected to be high, the statement concluded.